US Patent Issued to EPITHELION SCIENCE BIOTECH on Nov. 25 for "Irsogladine for the treatment of eosinophilic gastrointestinal diseases" (Spanish Inventors)

ALEXANDRIA, Va., Nov. 25 -- United States Patent no. 12,478,627, issued on Nov. 25, was assigned to EPITHELION SCIENCE BIOTECH S.L. (Barcelona, Spain).

"Irsogladine for the treatment of eosinophilic gastrointestinal diseases" was invented by Daniel Gassull Pallas (Barcelona, Spain) and Miquel Angel Gassull Duro (Barcelona, Spain).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides Irsogladine or a pharmaceutically acceptable salt thereof for use in the treatment and/or prevention of eosinophilic gastrointestinal diseases in mammals. The invention is useful in the treatment of eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic duodenitis, eosinophilic enteritis, eosino...